Molecular Physiology of G-CIMP+ Glioblastomas: Therapeutic Implications

A fundamental premise of gene therapy as it pertains to oncology is precision medicine, whereby therapeutic intervention is matched to unique vulnerabilities dictated molecular physiology of the cancer [1]. Cancers previously thought to be single clinical entities are now stratified based on these molecular physiologies [2]. As an example, glioblastoma, the most common form of primary adult brain cancer [3], is now recognized as an umbrella term that encapsulates a spectrum of subtypes that are defined by shared molecular physiologies [4]. A notable glioblastoma subtype involves the Glioma CpG IslandMethylator (G-CIMP) phenotype.